Patient‐reported quality of life (QOL) following tisagenlecleucel (tisa‐cel) infusion in adult patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)

By Fowler NH, Dickinson M, Martinez-Lopez J, et al
Published June 18, 2021

Key Takeaways

Given patient-reported QoL represents a crucial endpoint in the single-arm phase II ELARA trial of tisa-cel, which has showed efficacy as well as favorable safety profiles in adult pts with r/r FL, researchers herein report patient-reported QoL data prior to as well as following tisa-cel infusion in ELARA. Patients who were considered eligible were aged ≥18 y, had r/r FL (grades 1-3A) following ≥2 lines of therapy or had failed autologous stem cell transplant. Clinically meaningful improvements in QoL were evident in 40%-49% of pts, based on Functional Assessment of Cancer Therapy-Lymphoma and Short Form-36 Health Survey v2 at months (Mo) 3. No deterioration of QoL was seen in 68%-83% of pts. At Mo 6, the observed trends were similar. Findings revealed that tisa-cel infusion conferred clinically meaningful improvements in QoL of patients in this study.

Read the full article on Hematological Oncology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter